We back greatscienceand enable novelsolutions

Accelerator Life Science Partners (ALSP) is a US and Singapore-based early-stage life science accelerator and investment firm that creates and builds biotech companies based on innovative science.

The company catalyses the development and commercialisation of breakthrough biotech innovations by providing a holistic toolkit and leveraging its network and entrepreneurial expertise to accelerate the establishment and operation of early-stage biotech companies.

Allay Therapeutics is a US and Singapore-based biotech company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians.

The company’s proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates which provide pain relief within a targeted site over weeks.

CoVBio is developing booster vaccines and therapeutics that are effective against variants of SARS-2 beta coronavirus.

The company’s booster pan-sarbecovirus vaccine will protect against future variants and future crossovers of related coronaviruses from animals to humans.

Engine Biosciences is a Singapore and US-based company that develops precision medicine-based therapies for cancer and other diseases, using machine learning and large-scale experimental biological data generation and testing to decipher complex genetic networks.

The company’s proprietary technology platforms seek to integrate vast and differentiated human and disease datasets, machine learning, combinatorial genetics experiments, and in-house drug discovery to identify and develop promising drug targets for specific patient genetic and treatment contexts. Engine Biosciences’ technologies enable researchers and drug developers to feed and advance their therapeutics pipelines to treat unmet medical needs across a range of diseases.

Hummingbird Bioscience is a data-driven multidisciplinary team discovering and developing transformative precision biotherapeutics for hard-to-treat diseases. Leveraging computational and systems biology, the company’s proprietary approach has yielded wholly owned clinical-stage drug candidates now in development.

Lightstone Ventures is a global venture capital firm investing in early stage, therapeutic-oriented companies across the life science spectrum, as well as opportunistic late-stage companies.

Operating in Menlo Park, Boston, Ireland and Singapore, the company aims to empower founders to bring innovative therapeutics to patients.

MediSix Therapeutics is a Singapore-based immune engineering company that develops novel cellular therapies to address T-cell malignancies and autoimmune diseases.

The company has developed a technology platform on genetic engineering that utilises proprietary immune engineering approaches to generate T-cells for effective immune cell therapies.

Nuevocor is a Singapore-based biotech company developing targeted gene therapies to restore heart function through a deep understanding of fundamental mechanisms underlying genetic cardiac diseases.

The company is founded and advised by leaders in mechanobiology, cardiac disease and gene therapy. Its lead candidate treats the underlying biomechanical cause of LMNA dilated cardiomyopathy, while its PrOSIA mechanobiology platform enables target discovery and validation for additional genetic cardiomyopathies.

Paratus Sciences is committed to improving human health and health security by understanding the exceptional biology of bats. The company is focused on identifying and developing human therapeutics for diseases of high unmet need, including inflammation, virology, metabolism, oncology, and autoimmune disorders.

Polaris Partners aims to accelerate the commercial and therapeutic potential of disruptive healthcare and technology companies across the innovation cycle. By partnering with passionate entrepreneurs with transformational science, Polaris’ Fund fosters creation and growth of companies through an active investment model.

Sunbird Bio is a developer of next-generation diagnostic platforms to provide faster and more accurate outcomes in molecular diagnostics across a wide range of diseases including infectious diseases, neurodegenerative diseases and cancer.

The company’s vision is to improve lives by providing clarity and accessibility in diagnostic testing, to better inform healthcare decisions and outcomes.